

Contents

SECTION 1 WHO ARE WE?

Major milastanas	0
vialor milestones	Z

SECTION 2

Immune inflammatory diseases	.6
Non-melanoma skin cancer	.7
Other skin diseases	.8

SECTION 3

SECTION 4

Our R&D Centre	10
Pipeline	11
Recent collaborations	12

SECTION 5

SECTION 1 WHO ARE WE?

Almirall is a global pharmaceutical company dedicated to medical dermatology. For 80 years, we have closely collaborated with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients' needs.

The company, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange. Almirall (total revenue in 2023: €898.8 MM, 1900 employees globally) has a direct presence in 21 countries and affiliates in over 70 others.

"Making a difference to people with skin diseases is at the heart of Almirall's mission. Understanding patients and their needs is the basis of our focus on delivering effective and impactful treatments –from scientific innovation and development to product marketing."

Carlos Gallardo Piqué, Chairman and CEO of Almirall.

At Almirall, we are dedicated to medical dermatology. We are proud of our heritage, our deep understanding of skin diseases, patients, and dermatologists, our focus on science and innovation, and the close partnerships we have with the dermatology community around the world. We think in generations and have a long-term view of our contributions to dermatology and society. Our passion for medical dermatology enables us to develop and deliver new and impactful treatments for skin diseases to transform our patients' world by helping them to realise their hopes and dreams for a healthy life. By closely collaborating with the dermatology community, we build on the insights we gather from both medical professionals and patients. This kind of collaboration strengthens our dedication to becoming a global leader in medical dermatology.

While maintaining our focus on medical dermatology, **we complement our portfolio with other therapeutic divisions**, such as central nervous system, cardiovascular and gastrointestinal, amongst others. We provide medical solutions, and a product portfolio marketed through **15 offices**, operating in 20 countries in Europe and America. Our **agreements with strategic partners in over 90 countries** on the 5 continents also contribute to our global business model.



MAJOR MILESTONES

1944	Foundation of Laboratory Almirall, S.A.
1960	Almirall starts its research and development activities.
1984	Launch of the antacid almagate in Spain.
1990	Launch of the antihistame ebastine in Spain and concession of licences on an international scale.
1997	Merger between Almirall and Prodesfarma.
2006	Official opening of the new R&D Centre in Sant Feliu de Llobregat (Barcelona, Spain).
2007	Almirall is listed on the Spanish Stock Exchange Market. Acquisition of Hermal, a European prescription dermatology business of Reckitt Benckiser.
2012	Launch of aclidinium for the treatment of Chronic Obstructive Pulmonary Disease (COPD) in Europe marketed as Eklira® Genuair® and Bretaris® Genuair®. In the US, it is marketed as Tudorza™ Pressair™.
2013	Acquisition of Aqua Pharmaceuticals, a US-based specialty dermatology company.
2014	Almirall transfers the rights of its respiratory franchise to AstraZeneca.
2015	Acquisition of Poli Group, a pharmaceutical company which specializes in dermatology, and that is the world leader in nail diseases.
2016	Licensing agreement with Sun Pharmaceutical Industries Ltd. for the development and commercialization of tildrakizumab, a novel biologic treatment for patients with moderate-to-severe plaque psoriasis, within Europe.
2017	Launch in Europe of Skilarence®, a new oral formulation of dimethyl fumarate developed by Almirall for the treatment for patients with moderate-to-severe chronic plaque psoriasis. Agreement with Athenex to develop and commercialize tirbanibulin in the US and Europe for the treatment of actinic keratosis.



2019	Launch of Seysara® (sarecycline) in the US. Exclusive license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and other indications in Europe.
2020	FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis.
2021	License agreement with MC2 Therapeutics for European rights to Wynzora® Cream for treatment of plaque psoriasis. European Commission approval and launch of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis. Licensing Agreement with Ichnos Sciences for First-in-Class IL-1RAP Antagonist Monoclonal Antibody.
2022	Launch of Wynzora® Cream in Europe for the treatment of plaque psoriasis. Licensing agreement with Simcere for IL-2muFc.
2023	European Commission and MHRA approval of EBGLYSS® (lebrikizumab) for moderate- to severe atopic dermatitis and launch in Germany. SBTi validates Almirall's emission reduction targets for 2030 and its net-zero emissions goal for 2050. Bispecific antibody license agreement with EpimAb Biotherapeutics.
2024	Exclusive license agreement with Novo Nordisk for rights of NN-8828 in certain fields, including immune inflammatory dermatological diseases. Exclusive license agreement with Eloxx Pharmaceuticals for the asset ZKN-013 for rare dermatological diseases. Completion of a decentralized procedure in Europe for the treatment of mild-to- moderate fungal nail infection with efinaconazole.



ALMIRALL IN FIGURES

15 offices located in Europe and US

Operating in 20 countries

Almirall products marketed in over 100 countries on the 5 continents.



1,904 employees

36 nationalities represented.

Total Revenues (FY 2023): €894.5 MM

Net Sales in dermatology (FY 2023): €465.2 MM: 52% of Total Sales

Investment in R&D (FY 2023): €111 MM: 12.4% of total Net Sales



Breakdown of Almirall's 10 top-selling brands (2023)

Products	Proprietary/In-licensing	€MM
llumetri®	In-licensing	166.4
Ebastel® franchise	Proprietary	62.9
Ciclopoli® franchise	Proprietary	51.6
Crestor®	In-licensing	44.0
Sativex [®] franchise	In-licensing	36.4
Almax®	Proprietary	36.3
Decoderm [®] franchise	Proprietary	32.7
Skilarence®	Proprietary	23.4
Efficib® / Tesavel®	In-licensing	23.2
Solaraze®	In-licensing	22.0



SECTION 2 KEY DISEASES WE COVER IN DERMATOLOGY

We currently focus on three main disease categories: immune inflammatory diseases, non-melanoma skin cancer, and rare diseases. Our immune inflammatory disease portfolio includes cutting-edge franchises for atopic dermatitis and psoriasis. In non-melanoma skin cancer, our technologies address conditions like Our therapeutic focus actinic keratosis. For rare diseases, we are committed to developing new solutions for some of the over 1,000 rare dermatological conditions, particularly as more than 90 percent lack existing treatments. This includes tackling challenging conditions such as autoimmune bullous diseases, palmoplantar pustulosis, and ichthyosis.

IMMUNE INFLAMMATORY DISEASES

Atopic dermatitis (AD), or atopic eczema, is a non-contagious, chronic inflammatory disease characterized by recurrent skin inflammation, often associated with intense pruritus or itching. Beyond physical symptoms such as dryness, itchiness, redness, and inflammation, this condition significantly impacts emotional wellbeing and disrupts the academic, social, and professional lives of those affected.¹



EBGLYSS[•] (lebrikizumab) is a biologic treatment specially developed to target the protein IL-13 with high precision and affinity, selectively inhibiting its downstream signalling pathway with high potency.^{ii,iii,iv,v} Lebrikizumab represents a **significant step forward for patients with moderate-to-severe AD** not controlled with topical therapy thanks to its selective mechanism of action,ⁱⁱⁱ proven short and long-term efficacy and safety demonstrated for up to 2 years,^{vi,vii,viii} and a monthly maintenance dosing for all patients.^{ix}

Psoriasis, impacting an estimated 60 million individuals globally,^x is a chronic, autoimmune skin disorder characterized by inflammation. Physical symptoms of psoriasis are often painful and disfiguring, having a broad impact on patients' lives and mental health. Almirall is the unique among European biopharmaceutical companies, addressing this need by offering a comprehensive range of treatments, encompassing products from topical solutions to oral systemics and biologics, catering to the full spectrum of the condition.

llumetri® (tildrakizumab) is a biologic treatment that targets the interleukin-23 (IL-23) indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Wynzora[•] cream is a once-daily topical treatment for adults with mild-to-moderate plaque psoriasis, including the scalp.^{xi}

Skilarence[•] (dimethyl fumarate) is an oral medicine for treating adults with moderate to severe plaque psoriasis. It is indicated as a first-line treatment and long-term maintenance therapy. Notably, it is also the first and only European Commission-approved fumaric acid ester (FAE) for the treatment of adults with psoriasis in need of systemic medicinal therapy.

NON-MELANOMA SKIN CANCER

Actinic keratosis (AK), characterized by rough, scaly skin lesions, is a common diagnosis in dermatology. These lesions typically develop on sun-exposed areas of the skin, such as the face, ears, lips, balding scalp, forearms, backs of hands, and lower legs. As a chronic and recurrent condition, AK increases the risk of suffering squamous cell carcinoma (SCC), which is the second most common type of skin cancer.^{xii} Early detection and treatment of AK lesions are crucial in mitigating the risk of developing SCC in due course.

Klisyri[•] (tirbanibulin) is an innovative topical treatment with a selective antiproliferative mechanism of action. It represents a significant step forward in the treatment of AK due to its short treatment protocol (a once-daily application for 5 consecutive days), proven efficacy, safety profile, and good tolerability results. Klisyri[®] received a recommendation in the German AK treatment guidelines, published in 2023.

Actikerall[•] is a lesion-directed topical for the treatment of hyperkeratotic actinic keratosis. Easy to use (applied locally once daily), it is a highly effective treatment for mild-to-moderate AK.



Solaraze[®] is a nonsteroidal anti-inflammatory topical treatment, its active ingredients are diclofenac (3%) and hyaluronic acid (10%) used to treat AK lesions and adjacent sun-damaged skin.

OTHER SKIN DISEASES

Acne, characterized by the chronic development of papules, pustules and nodules, is the eighth most prevalence disease in the world, affecting an estimated 9.4% of the world's population. For moderate-to-severe non-nodular acne vulgaris, Almirall commercializes **Seysara**[•] (sarecycline), a first-in-class tetracycline-derived oral antibiotic, in the US. Besides, we are working on a future expansion to China.

Onychomycosis, also called nail fungus, is the most common nail infective disorder, and is characterized by the appearance of white, yellow or black spots at the edge or at the base of the nail, near the cuticle. **Ciclopoli®**, a once-daily topical treatment indicated for mild-to-moderate fungal infections of the nails, is one of Almirall's flagships in dermatology. **Efinaconazole**, a triazole antifungal compound also indicated for the treatment of mild-to-moderate fungal infection of the nail in adults and children, recently completed the decentralized regulatory procedure in Europe, which marks the final phase before European countries can grant national marketing authorizations.



SECTION 3 OTHER KEY PRODUCTS

At Almirall, our perceptive and committed management style has always been based on meeting patients' needs. In doing so, we have always recognized the need for diversification. While our primary focus remains medical dermatology, our portfolio goes beyond.

Our dermatology areas are completed with other innovative licensed drugs, such as **Sativex®** (THC:CBD), a cannabis-based medicine containing tetrahydrocannabinol (THC) and cannabidiol (CBD). It is indicated for the treatment of resistant multiple sclerosis spasticity and associated cramps, pain, mobility impairment, bladder dysfunction, and sleep disorders. Sativex[®] is an oral sublingual spray.

In the cardiovascular area, Almirall entered into a license agreement with AstraZeneca in 2017 to distribute and commercialize in Spain **Crestor®** and **Provisacor®**, both of which contain the active ingredient rosuvastatin and are indicated as cholesterol-lowering treatments.

Our other therapeutic divisions, such as CNS (central nervous system) and gastrointestinal, amongothers, provide effective solutions for patients' needs. Key products such as **Ebastel®**, marketed in over 34 countries worldwide, and **Almax®**, born in our own R&D laboratories, are positioned among our top 10 selling brands.

Almirall also acquired the rights, in 2023, to **Prometax®** (rivastigmine patches), a daily transdermal medicated patch used to alleviate Alzheimer's-related dementia symptoms and the **Physiorelax®** franchise (Helenalin2), a brand of topical products of natural origin, that massage the muscles and ligaments.



SECTION 4

We consider innovation the cornerstone of our success in medical dermatology through providing impactful solutions to patients and the medical community. Our R&D efforts and pipeline to develop innovative products are exclusively focused on medical dermatology. We have consistently focused on our leading R&D capabilities in skin biology and product development - with over 1 bn Euros investment in R&D over the last 10 years - and will continue to prioritise this in the future.

We recognise the fundamental and significant impact that dermatological conditions can have on people's lives, their families, and loved ones. That's why we push the boundaries of science and develop novel technologies that help to address the broad impact dermatological conditions. Our goal is to cover a broad spectrum of dermatological indications including common diseases as well as some rare conditions with a high burden on individuals.

OUR R&D CENTRE

Nestled in the vibrant biomedical science and healthcare innovation hub of Barcelona, we are proud of our dermatology-dedicated pharmaceutical R&D centre near Barcelona, in an emerging hub for biomedical science and healthcare innovation.

Our leading scientists and innovation experts (about 250 R&D people) are fully dedicated to advancing the scientific knowledge of skin diseases and identifying new treatments utilising a range of technologies.



Our focus on R&D in medical dermatology and our constant strive to advance the scientific understanding of skin and skin diseases sets us apart from other companies of our size. It has made us a key player in the expanding pharma- and life sciences research in Europe.

Building on its open innovation platform established in 2023, Almirall has announced the launch of The Hive, welcoming ADmit Therapeutics, specializing in early detection of Alzheimer's and other neurodegenerative diseases, and Microomics, experts in metagenomic analysis using advanced DNA sequencing technologies. The new joiners will complement Almirall's network that includes ZeClinics, a Contract Research Organization (CRO) spezialising in genetics research using zebrafish as a model organism, and Centrient Pharmaceuticals, a leader in sustainable biosynthetic pharmaceutical products.

PIPELINE

Our focus in R&D is dedicated to autoimmune-mediated skin diseases such as atopic dermatitis and hidradenitis suppurativa, rare dermatological diseases and non-melanoma skin cancers such as BCC and SCC. This includes highly prevalent indications, but also less prevalent indications or rare diseases which are often not of interest for larger pharmaceutical companies (e.g., onychomycosis, epidermolysis bullosa or actinic keratosis).

Our approach is to look for the best and the most suitable treatment modalities to target dermatological diseases, e.g., therapeutic proteins, small molecules, mRNA-based therapeutics, amongst others. Our collaborative approach allows us to work closely with leading experts around the globe to innovate and develop novel approaches such as AI-based drug discovery, PROTACS, bispecific monoclonal antibodies, and mRNA therapies.

Molecule name	Indication	Phase I	Phase II	Phase III	Under registration	Geography
Recent approvals						
efinaconazole	Onychomycosis		6			• •
Life-cycle manage	ement (label extension)					
sarecycline	Acne 🧧					
tirbanibulin	Actinic keratosis (LF)					0
tildrakizumab	Psoriatic arthritis					0
lebrikizumab	Atopic Dermatitis pediatric					0
NMEs						
anti-IL-21 mAb	Autoimmune dermatology					6
anti-IL-1RAP mAb	Autoimmune dermatology					6
IL-2muFc	Autoimmune disease					O .
ZKN-013	Rare Dermatology					0



RECENT COLLABORATIONS

Our R&D approach is highly collaborative. We choose the best path to deliver novel treatments either inhouse, through external collaborations, or as part of licensing agreements. Our partnerships with academic centres of excellence in dermatology worldwide allow us to further build the molecular understanding of disease biology in dermatology indications.

We engage with public initiatives, and access innovative technology platforms through strong partnerships. With our partners we share our passion for science that allows us to tap into the best academic and medical talent available globally. This commitment to cooperation is forged through initiatives such as AlmirallShare, our open innovation platform, and Almirall SHINE, a science-driven initiative dedicated to consolidating an academic research collaboration network with centres of excellence in dermatology. This allows the company to share efforts, resources, and risks to discover innovative treatments in the field of medical dermatology.

CRG: To identify molecular pathways and biomarkers specific to atopic dermatitis.

Microsoft: to drive innovation and digital transformation, advance the research of medical solutions for dermatological diseases, and accelerate the digital transformation of the company.

Absci: To harness generative AI for developing and commercializing novel therapeutics targeting chronic dermatological diseases.

Etherna: To pioneer mRNA-based therapies for serious skin conditions, including non-melanoma skin cancer. While joint research efforts are planned, Almirall will lead the clinical and commercial stages.




SECTION 5 SUSTAINABILITY

At Almirall, sustainability is more than a commitment; it is a core pillar that drives our mission to create long-term value, sustainability plays an essential role in how we conduct our work at Almirall. Environmental, social and governance considerations are a core part of our corporate strategy.

Our "Act4Impact 2030 Sustainability Strategy" embedded in the Almirall's ambition to become a global leader in medical dermatology, is built on four strategic pillars – "Planet", "People", "Patients", and "Partners" – and is guided by our unwavering "Principles". By reducing our environmental footprint, fostering responsible partnerships, and prioritizing the well-being of our employees and patients, we are dedicated to making a positive impact.

Our sustainability efforts are overseen by a dedicated Sustainability Committee, which reports directly to the Management Board. This committee ensures that our actions are aligned with our corporate sustainability strategy and the United Nations 2030 Agenda.





Roadmap to decarbonization

In July 2023, we re-confirmed our commitment to decarbonizing our operations by validating our goal of reaching net zero emissions by 2050 across our value chain by the Science Based Targets initiative (SBTi). To achieve this, we have a strong decarbonization plan in place with different lines of action, such as energy efficiency, renewable energy consumption, reduction of natural gas consumption, sustainable mobility, and supplier engagement programmes, among others.

Renewable sources already make up 100% of our total electricity consumption. We plan to continue expanding our photovoltaic capacity up until 2030. In addition, we are working to reduce emissions from our vehicle fleet by more than 50% by 2030. As part of this, in 2023, we launched net-zero-aligned policies for executive vehicles and the sales network in Spain.

Remuneration, integration and equality

Our compensation plans promote a culture of excellence, considering the level of contribution of each employee's position and performance. We are committed to achieving the Sustainable Development Goals (SDGs) within the UN's 2030 agenda. Thus, we work every day to implement policies that promote gender equality (SDG 5) and the reduction of inequalities (SDG 10).

Our Equality Plan is a core part of our approach to equal opportunities in our organization, and our equality agents monitor all of its actions to promote and improve women's access to positions of responsibility and to avoid gender-based discrimination in recruitment and pay. In May 2022, we launched the EQUAL project, which helped to establish an equitable salary structure for all countries. In the same vein, in 2023, we worked on aligning different remuneration criteria globally including local perspective, which included reviewing fleet policies and gender pay gap calculations.

Consolidation and improvement of our score in the main ESG assessment systems:





Contact Information

ALMIRALL

Corporate External Communications

Carla Arrieta / Èrika Paloschi

corporate.communication@almirall.com

iii Gonçalves F, et al. Selective IL-13 inhibitors for the treatment of atopic dermatitis. Drugs Context 2021;10:2021-1-7.

iv Okragly A, et al. Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-1547.

v Ultsch M, et al. Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339.

vi Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med. 2023;doi:10.1056/ NEJMoa2206714.

vii Simpson EL et al. Efficacy and safety of Lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. Published online January 11, 2023; doi:10.1001/jamadermatol.2022.5534.

viii Blauvelt A, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebocontrolled phase III trials. British Journal of Dermatology. 2023; ljad022, https://doi.org/10.1093/bjd/ljad022.

ix Guttman-Yassky E, et al. Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. Presented at the Fall Clinical Dermatology Conference; October 20, 2023.

x Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020 May;36:m1590. doi:10.1136/bmj.m1590.

xi Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M; trial investigator group. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):228–236. doi: 10.1111/jdv.17734.

xii Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007 Sep;33(9):1099-101. doi: 10.1111/j.1524-4725.2007.33224.x.



i Koszorú K, Borza J, Gulácsi L, Sárdy M. Quality of life in patients with atopic dermatitis. Cutis. 2019 Sep;104(3):174-177.

ii Moyle M, et al. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756–768.